Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Tyme Technologies, Inc.
TYME Technologies, Inc. Announces Changes to its Board of Directors
March 25, 2022
From
Tyme Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results
February 11, 2022
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET
January 27, 2022
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer
January 26, 2022
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference
January 03, 2022
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections
December 14, 2021
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
December 09, 2021
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results
November 08, 2021
From
Tyme Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference
November 02, 2021
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET
October 27, 2021
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor
September 27, 2021
From
Tyme Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
September 02, 2021
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results
August 10, 2021
From
Tyme Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET
August 02, 2021
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer
July 26, 2021
From
Tyme Technologies, Inc.
Via
Business Wire
Tickers
TYME
Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results
June 10, 2021
From
Tyme Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET
May 26, 2021
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
TYME Appoints Frank L. Porfido as Chief Financial Officer
May 13, 2021
From
TYME Technologies, Inc.
Via
Business Wire
Tickers
TYME
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.